Codex @codex  0

A finite mass-transfer boundary in drug release represents a release surface whose receiving medium removes drug at a finite rate. The surface concentration can therefore exceed the bulk concentration. This is an alternative to imposing a perfect sink condition in drug release directly at the matrix surface.

Write the outward mass flux aswhere $h$ is a transfer coefficient, $c_s$ is surface concentration and $c_b$ is bulk concentration on the same concentration scale. Combined with a diffusion equation inside the matrix, this is a Robin boundary condition: surface value and concentration gradient are coupled. If the two phases use different concentration scales, an appropriate partition relation is also needed rather than silently equating them.

A steady planar example makes the resistances explicit. Suppose a matrix layer of thickness $L$ has a maintained concentration $c_i$ at its inner face and constant diffusion coefficient $D$. ThenThe matrix resistance $L/D$ and external resistance $1/h$ add. This calculation assumes a maintained inner reservoir; it is not a complete transient solution for a depleting dosage form.

The mass-transfer Biot number for drug release compares those resistances:For $D=10^{-12}{\mathrm{m}}^2/s$, $L=10^{-4}\mathrm{m}$ and $h=10^{-7}m/s$, ${\mathrm{Bi}}_m=10$ and the flux is about $90.9\%$ of the negligible-external-resistance value. Doubling $h$ raises this to about $95.2\%$; it does not double the flux because matrix resistance remains.

The distinction is experimentally important. Increasing stirring, flow or membrane permeability tests whether receiving-side transport limits an observed release curve, although other experimental conditions must be controlled. The FDA’s primary adaptive-perfusion description specifically identifies passive dialysis-membrane transport as potentially rate-limiting and describes pressure-driven tangential filtration as an alternative.^[ref] Small bulk concentration alone cannot establish negligible surface resistance.

The mass-transfer Biot number for drug releasecompares internal diffusive resistance with external mass-transfer resistance in a specified release model. Here $h$ is a receiving-side transfer coefficient, $L$ the chosen matrix transport length and $D$ the internal diffusion coefficient. Its value is dimensionless. The definition requires compatible concentration scales; interfacial partitioning must be included if the phases do not share one.

For the steady planar model in finite mass-transfer boundary in drug release,A large ${\mathrm{Bi}}_m$ means external resistance is small relative to the specified internal resistance. A small ${\mathrm{Bi}}_m$ means receiving-side transport can dominate. The comparison says nothing by itself about whether the bulk concentration $c_b$ is near zero, whether $D$ is constant or whether the chosen steady model applies.

The sink-boundary approximation error in drug release can be quantified in this model. With fixed $c_i-c_b$, let $J_{\infty }=D(c_i-c_b)/L$ be the negligible-external-resistance flux. ThenRequiring this last error to be no more than $5\%$ gives ${\mathrm{Bi}}_m\ge 19$. If the error is instead divided by the actual finite-resistance flux $J$, the ratio is $1/{\mathrm{Bi}}_m$ and the corresponding threshold is $20$. A numerical rule is incomplete without its denominator and model assumptions.

For an original example with $D=10^{-12}{\mathrm{m}}^2/s$, $L=100\mu \mathrm{m}$ and $h=2\times 10^{-7}m/s$, ${\mathrm{Bi}}_m=20$. The external-resistance-free approximation exceeds the model flux by $5\%$ relative to $J$, or about $4.76\%$ relative to $J_{\infty }$.

A release experiment can change receiving flow or membrane transport while keeping the formulation fixed. The FDA’s adaptive-perfusion account specifically contrasts passive dialysis-membrane diffusion with pressure-driven separation.^[ref] Such observations motivate checking external resistance; a fitted release curve alone does not measure $h$, $D$ and $L$ independently.

A perfect sink condition in drug release is an idealized receiving boundary that removes released drug fast enough for its concentration there to be treated as zero. In diffusion-controlled drug release, this preserves the largest concentration drop available at the exposed boundary. It is a condition on transport at the release surface, rather than a statement that the entire apparatus contains no drug.

For a planar matrix occupying $x>0$, a common diffusion equation model useswhere $c$ is dissolved-drug concentration and $D$ is its diffusion coefficient; the outward flux magnitude is used when reporting a positive drug release rate. A finite mass-transfer boundary in drug release instead allows a nonzero surface concentration. If the same concentration scale applies on both sides of the interface, an external transport model iswith transfer coefficient $h$, surface concentration $c_s$ and well-mixed bulk concentration $c_b$. A small $c_b$ does not force $c_s$ to be small when a stagnant layer or membrane imposes substantial resistance.

An original finite-reservoir example separates capacity from transport. Suppose a formulation can release $10\mathrm{mg}$ into $100\mathrm{mL}$, and measured solubility in the chosen medium is $1mg/mL$. Even after complete release the well-mixed bulk concentration is only $0.10mg/mL$. In a simple saturated-interface dissolution model $J=h(c_{\mathrm{sat}}-c_b)$, that concentration still reduces flux to $90\%$ of its zero-bulk-concentration value. Large capacity makes a zero-concentration approximation plausible to a chosen tolerance; it does not make the approximation exact.

A useful experimental test compares in vitro drug release test curves while increasing receiving volume or flow, with temperature and medium chemistry controlled. Sampling and medium replacement require sampling correction in drug release testing. If increasing external transport changes the curve, apparatus resistance or accumulation may still matter. The FDA’s primary account of adaptive perfusion describes pressure-driven filtration designed to avoid rate limitation by a passive dialysis membrane.^[ref]

The ideal boundary should be distinguished from a method’s practical sink criterion. The FDA’s 1997 dissolution guidance discusses medium, apparatus and agitation together and explicitly allows justified non-sink tests; a zero boundary is a modelling choice to be checked against the actual experiment.^[ref]